Orbus Pharma Inc.

Orbus Pharma Inc.

November 13, 2006 17:38 ET

Orbus Announces Appointment of New Director

TORONTO, ONTARIO--(CCNMatthews - Nov. 13, 2006) - Orbus Pharma Inc. (TSX:ORB) ("Orbus") is pleased to announce that Rudy J. Fernandes has been appointed to the Board of Directors of Orbus Pharma Inc. Mr. Fernandes has over 30 years of experience in the pharmaceutical business in Canada and USA and was a former executive at Wyeth Pharmaceuticals, Canada, CIBA-GEIGY Canada Ltd & at Novartis. Mr. Fernandes responsibilities over the years included business development, market access, marketing and sales. Mr. Fernandes holds an honours Bachelor of Science degree in Microbiology and was inducted into the Canadian Healthcare Marketing Hall of Fame in 2004.

"We are delighted to welcome Rudy Fernandes to the Company at a time when we are anticipating receiving European approvals on our generic oxcarbazepine and cefuroxime axetil drug applications. His vast experience in the sales and marketing of pharmaceutical products and his valuable contacts in the healthcare sector will be definite assets as we enter into the next stage of our business development" said Jeff Renwick, President and CEO of Orbus. "His experience in this regard will be highly valued as we move forward."

Orbus Pharma Inc., listed on The Toronto Stock Exchange under the symbol ORB. Orbus pursues a strategy of generating revenue through the licensing of generic drug developments, as well as the manufacturing and selling of pharmaceutical products. For more information please visit www.orbus.ca.

Forward looking statements

Certain statements in this disclosure are "forward-looking statements", which reflect management's expectations regarding the Company's future growth, results of operations, performance and business prospects and opportunities. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Many factors could cause results to differ materially from the results discussed in the forward-looking statements, including risks related to dependence on key suppliers, economic conditions, competition, regulatory change, foreign exchange rates, and interest rates, among others. Although the forward-looking statements are based on what management believes to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements.

Contact Information

  • Orbus Pharma Inc.
    Jeffrey W. Renwick
    President & CEO
    (905) 943-9444